雷贝拉唑三联疗法治疗幽门螺杆菌相关性消化性溃疡的临床研究

目的探讨雷贝拉唑三联疗法治疗幽门螺杆菌相关性消化性溃疡的临床效果。方法选取本院2011年1月～2012年6月收治的幽门螺杆菌相关性消化性溃疡患者84例,随机分为两组。42例患者为对照组采用奥美拉唑三联疗法：奥美拉唑20mg/次、克拉霉素500mg/次、阿莫西林1000mg/次,2次/d,疗程为7d,后改为奥美拉唑20mg/次,1次/d,疗程为4周。42例患者为观察组采用雷贝拉唑三联疗法：雷贝拉唑20mg/次、克拉霉素500mg/次、阿莫西林1000mg/次,2次/d,疗程为7d,后改为雷贝拉唑20mg/次,1次/d,疗程为4周。比较两组患者疗程结束时症状缓解情况、溃疡愈合情况、幽门螺杆菌清除情况、不良反应情况。结果观察组症状缓解率为88.1%、治愈率为85.7%、幽门螺杆菌清除率为95.2%,均明显高于对照组的69.0%、66.7%、81.0%,差异均有统计学意义（P〈0.05）。观察组不良反应发生率（7.1%）低于对照组（19.0%）,差异无统计学意义（P〉0.05）。结论雷贝拉唑三联疗法治疗幽门螺杆菌相关性消化性溃疡具有显著的临床疗效,可以明显缓解患者的临床病症,提高溃疡治愈率和幽门螺杆菌清除率,且不良反应较少,值得临床推广使用。

Clinical research on rabeprazole triple therapy in the treatment of helicobacter pylori related peptic ulcer

Objective To investigate the clinical effect on rabeprazole triple therapy in the treatment of helicobacter pylori related peptic ulcer. Methods Eighty-four patients with helicobacter pylori related peptic ulcer were selected in the hospital from January 2011 to June 2012, who were randomly divided into two groups. Forty-two patients used omeprazole triple therapy as the control group. Omeprazole 20 mg/time, clarithromycin 500 mg/time, amoxicillin 1 000 mg/time, 2 times/d, course of 7 d, later renamed omeprazole 20 mg/time, 1 time/d, course of 4 weeks. Forty-two patients used rabeprazole triple therapy as the observation group. Rabeprazole 20 mg/time, clarithromycin 500 mg/time, amoxicillin 1 000 mg/time, 2 times/d, course of 7 d, later renamed rabeprazole 20 mg/time, 1 time/d, course of 4 weeks. Symptom relief, peptic ulcer, helicobacter pylori clearance, adverse reaction were compared between two groups at the end of treatment. Results The observation group＇s symptom relief rate was 88.1%, cure rate was 85.7%, helicobacter pylori clearance rate was 95.2%, which were significantly higher than 69.0%, 66.7%, 81.0% of the control group. The difference was statistically significant （P 0.05）. Incidence of adverse reactions （7.1%） in the observation group was lower than that of the control group （19.0%）. The difference was not statistically significant （P 0.05）. Conclusion Rabeprazole triple therapy in the treatment of helicobacter pylori related peptic ulcer has obvious clinical curative effect, which can obviously relieve the clinical symptoms of patients and improve the cure rate of ulcer and helicobacter pylori eradication rate. That has less adverse reaction. That is worthy of clinical use.